A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect of the Aβ mAb drug class.

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

The UK’s research and development (R&D) funding agency ARIA has granted funds to anti-clinical research organisation (CRO) ...

DCTs were readily adopted during the pandemic, with many believing they were more sustainable, but experts are now ...

Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, ...

Results from Lundbeck's open-label portion of the Pacific trial saw bexicaserin able to elicit seizure reduction in treatment ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium on 3 April, Roche presented interim trial data for ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Previously referred to as NTLA-2001, nex-z is an in vivo ‘CRISPR-based’ therapy. Credit: Volha_R/Shutterstock. Intellia Therapeutics has commenced subject dosing in the randomised pivotal Phase III ...